A better understanding of cancer immunotherapy has identified the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a cytokine with the ability to target cancer cells whilst sparing non-malignant cells. The gene discussed is TNFSF10; the disease is cancer.